Navigation Links
UCB and Amgen Initiate Sclerostin Antibody Phase 3 Program in Patients With Postmenopausal Osteoporosis
Date:4/3/2012

BRUSSELS and THOUSAND OAKS, Calif., April 4, 2012 /PRNewswire/ -- UCB (Euronext Brussels: UCB) and Amgen (NASDAQ: AMGN) announced today the start of their sclerostin antibody (CDP7851/AMG 785) Phase 3 clinical trial program for the treatment of postmenopausal osteoporosis.

"We look forward to working with UCB on the CDP7851/AMG 785 Phase 3 program," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "Despite available osteoporosis therapies, there remains a significant need for additional treatment options that form new bone in women diagnosed with postmenopausal osteoporosis."

"Our sclerostin antibody project with Amgen is one of the most exciting pipeline programs in UCB's portfolio.  Data collected so far indicate the potential for a change of treatment paradigms in postmenopausal osteoporosis," said Prof. Dr. med. Iris Loew-Friedrich, Chief Medical Officer of UCB and Executive Vice-President Global Projects and Development. "We are delighted about the start of the Phase 3 program. The progress made to date encourages and motivates us as we work toward providing a new treatment option for women living with postmenopausal osteoporosis."

The Phase 3 program includes a multicenter, international, randomized, double-blind, placebo-controlled, parallel-group, two-year study in more than 5,000 postmenopausal women with osteoporosis.  The primary endpoint will evaluate the incidence of new vertebral fractures at 12 months. Initial results from the Phase 3 program are expected by the end of 2015.

CDP7851/AMG 785 is a humanized monoclonal antibody that binds to and inhibits sclerostin, a protein secreted by bone cells that inhibits bone formation. By binding to and blocking sclerostin, CDP7851/AMG 785 is designed to increase the amount of bone in the skeleton. With more than 75 million people worldwide suffe
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
2. Medarex to Receive Milestone Payment from Amgen
3. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
4. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
5. CDC Foundation Partners with Amgen, CDC to Reduce Infections Among Cancer Patients
6. Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)
7. Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting
8. Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes
9. Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP
10. Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
11. Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/5hkm2f/medical_oxygen ) has ... - Global Strategic Business Report" report to their ... for Medical Oxygen Systems in US$ Thousands by the ... & Regulators, and Oxygen Conserving Devices. The report provides ... , Japan , ...
(Date:4/17/2015)... 17, 2015   IBA Molecular, a global ... today that it has signed a definitive agreement to ... (IBAM NA), to Illinois Health and Science (IHS). Under IHS ... independent company headquartered in Dulles, Virginia ... of new product and footprint synergies. IBA Molecular is ...
(Date:4/17/2015)... TAIPEI , April 17, 2015 TWi ... fully-owned subsidiary, TWi Pharmaceuticals USA , ... in the United States.  It has been in close ... wholesalers and expects to have its own label specialty ... soon in the U.S. pharma market. According ...
Breaking Medicine Technology:Medical Oxygen Systems - 2015 Global Strategic Business Report Featuring Leading Players, Caire, Invacare & Philips Respironics 2Health Care System to Acquire IBA Molecular North America 2Health Care System to Acquire IBA Molecular North America 3
... and Safety of Combination Drug Therapies -, ... Life,Sciences, Inc. (Nasdaq: CALP ) today ... & Services (CDAS). These new services,will help ... therapies,and identify potentially harmful combinations before therapies ...
... WILMINGTON, Del., Nov. 30 AstraZeneca (NYSE:,AZN) announced ... in the,ZEST (ZACTIMA Efficacy Study versus Tarceva) study, ... investigational once-daily oral anti-cancer drug,vandetanib. Data from the ... a randomized, double-blind, multi-center Phase III study to,assess ...
Cached Medicine Technology:Caliper Life Sciences Introduces Drug Combination Services to Identify Synergistic Response of Compounds 2AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer 2
(Date:4/17/2015)... WA (PRWEB) April 17, 2015 ERGO-Pedic ... cushions is introducing two new products to help a ... low back pain relief are the second most common ... our first product, designed specifically to help relieve sitting ... Comfort Cushion, and thousands of happy customers later, we ...
(Date:4/17/2015)... (PRWEB) April 17, 2015 Alcohol and ... Dependence (NCADD) notes that drinking and driving has been ... At the same time, the link between alcohol and ... domestic abuse and violence and sexual assault, and their ... to the NCADD, 5.3 million adults in America were ...
(Date:4/17/2015)... 2015 “We have seen healing, a lot ... and present,” said Chaplain Shawn Kafader of Friendship Village. ... they had anything to contribute have created beautiful pieces of ... new art therapy program that was launched to benefit residents ... from School of the Art Institute in Chicago, worked as ...
(Date:4/17/2015)... D.C. (PRWEB) April 17, 2015 In ... issued the following statement: “On Wednesday April 15th, the ... and adopted a resolution recognizing the Armenian Genocide, “paying ... memory of the one-and-a-half million innocent Armenian victims who ... Christians (IDC) extols the EU for this timely and ...
(Date:4/17/2015)... (PRWEB) April 17, 2015 Representatives Jim ... Diagnoses and Treatment Act HR 1849 in congress on ... rates and treatment for patients with the genetic disease. ... the past, would be the first to create a ... appropriate treatment of hereditary hemorrhagic telangiectasia. This would effectively ...
Breaking Medicine News(10 mins):Health News:Seat Cushion Company Credits Customer Driven Design For Two New Products 2Health News:Narconon Arrowhead Raises Awareness on Alcohol Related Prevention 2Health News:Narconon Arrowhead Raises Awareness on Alcohol Related Prevention 3Health News:Healing At Friendship Village Due To Art Therapy 2Health News:In Defense of Christians Condemns Armenian Genocide 2Health News:In Defense of Christians Condemns Armenian Genocide 3Health News:House Representatives Introduce Bill to Fight Genetic Disease 2
... which men are at increased risk, scientists say , MONDAY, ... identified key gene variants tied to an increased risk of ... step toward understanding which men are at high risk for ... not been any clear genetic risk factors that can account ...
... 1 Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, ... the companies have begun enrolling patients in an international ... patients with non-squamous non-small cell lung cancer (NSCLC) who ... , "Nexavar has proven efficacy in liver cancer and ...
... Two of the nation,s most rapidly growing retained physician search ... Inc., Atlanta, GA, have agreed to merge their operations under ... not disclosed. , , Crutchfield Capital Corporation served ... "Successful mergers are built upon cultural fit, the integrity of ...
... and response at national and local level , , ... $1 million over the next three years through the Ryder ... response efforts, making it the newest member of the American ... (Logo: http://www.newscom.com/cgi-bin/prnh/20090108/RedCrossLOGO ) , ...
... on Rebuilding Revenue Base While Stabilizing Costs--, ... /PRNewswire-FirstCall/ - Vancouver, BC, Canada - Neovasc Inc. (TSXV: NVC), ... 31, 2009. , "The first quarter continued to show financial ... Neovasc on our most promising growth areas," said Alexei Marko, ...
... clinical recommendations encourage cardiologists to examine the mouth and periodontists ... June 1 Cardiovascular disease, the leading killer of men ... health issue contributing to 2,400 deaths each day. Periodontal disease, ... that support the teeth affects nearly 75 percent of Americans ...
Cached Medicine News:Health News:Researchers Spot Genes Linked to Testicular Cancer 2Health News:Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non-Small Cell Lung Cancer 2Health News:Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non-Small Cell Lung Cancer 3Health News:Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non-Small Cell Lung Cancer 4Health News:Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non-Small Cell Lung Cancer 5Health News:Unprecedented Merger Occurs in Retained Physician Search Industry 2Health News:Unprecedented Merger Occurs in Retained Physician Search Industry 3Health News:Ryder System, Inc. Joins the American Red Cross Annual Disaster Giving Program 2Health News:Ryder System, Inc. Joins the American Red Cross Annual Disaster Giving Program 3Health News:Ryder System, Inc. Joins the American Red Cross Annual Disaster Giving Program 4Health News:Neovasc Inc. Reports First Quarter 2009 Financial Results 2Health News:Neovasc Inc. Reports First Quarter 2009 Financial Results 3Health News:Neovasc Inc. Reports First Quarter 2009 Financial Results 4Health News:Neovasc Inc. Reports First Quarter 2009 Financial Results 5Health News:Neovasc Inc. Reports First Quarter 2009 Financial Results 6Health News:Neovasc Inc. Reports First Quarter 2009 Financial Results 7Health News:Neovasc Inc. Reports First Quarter 2009 Financial Results 8Health News:Neovasc Inc. Reports First Quarter 2009 Financial Results 9Health News:Neovasc Inc. Reports First Quarter 2009 Financial Results 10Health News:Neovasc Inc. Reports First Quarter 2009 Financial Results 11Health News:Healthy Gums and a Healthy Heart: The Perio-Cardio Connection 2Health News:Healthy Gums and a Healthy Heart: The Perio-Cardio Connection 3Health News:Healthy Gums and a Healthy Heart: The Perio-Cardio Connection 4
... biopsies of soft tissue. Lightweight and compact, ... control. Precise, rapid firing mechanism provides intact ... easy penetration into the specimen with less ... of cannula helps assure an intact tissue ...
... The Bard EXPRESS Seeding Cartridge System is ... delivering radioactive seeds and spacers into a ... Each cartridge has a(n): outer radiation safety ... synthetic absorbable spacers, integrally molded fitting that ...
... very easy to use Ambulatory Urodynamic recorder ... with practising urologists as an invaluable aid ... dysfunctions. The system offers the possibility to ... a natural bladder filling, extented over a ...
A compact mobile System Cart gives mobility within your department. The cart accomodates the Uromac Median data processor, desktop computer, printer and provides stowage space. Patient related transd...
Medicine Products: